Endocannabinoid-related levels differed in mania, but the study cannot show why

The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder.

The international journal of neuropsychopharmacology • • Highly Relevant
🤖

AI Summary

This study asked whether serum endocannabinoid-related molecules differ between mania and remission in people with bipolar disorder. Researchers measured PEA, OEA, 2-AG, anandamide, and CRP in 51 patients during a manic episode and 49 healthy controls; 32 patients were assessed again during remission. This was a human, within-patient observational comparison, not a treatment trial.

Compared with healthy controls, patients had significantly lower PEA and OEA levels during mania. During remission, PEA and OEA levels did not differ significantly from controls; in the direct comparison of mania with remission, only PEA was significantly lower during mania. The findings suggest these molecules may merit further study as possible mood-related biomarkers, but this abstract cannot establish that they cause mood changes or are useful for diagnosis or treatment. This is an abstract-based summary; the study’s observational design and the smaller remission follow-up group limit what can be concluded.

💡 Key Findings

1
In 51 patients with bipolar disorder, serum PEA and OEA were significantly lower during mania than in healthy controls.
High
80%
2
Among the 32 patients reassessed during remission, PEA and OEA levels did not differ significantly from healthy controls.
High
80%
3
In comparisons within the same patients, only PEA was significantly lower during mania than remission; the study does not establish causation or clinical usefulness as a biomarker.
High
80%

📄 Original Abstract

OBJECTIVE: Endocannabinoids are involved in biological processes relevant to mood regulation, and altered circulating levels have been reported in bipolar disorder (BD). However, serum endocannabinoid levels have not previously been examined across mania and remission within the same patients and compared with healthy controls. This study evaluated serum palmitoylethanolamide (PEA), oleoylethanolamide (OEA), 2-arachidonoylglycerol (2-AG), anandamide (AEA), and C-reactive protein (CRP) levels in patients with BD during manic episodes and remission and in healthy controls. METHODS: Fifty-one patients diagnosed with BD, manic episode, according to DSM-5-TR criteria, and 49 healthy controls were included. After discharge, 32 patients who attended outpatient follow-up visits were re-evaluated during remission. Serum PEA, OEA, 2-AG, AEA, and CRP levels were measured in all participants. Patients with BD were additionally assessed using the Young Mania Rating Scale, Hamilton Depression Rating Scale, and Positive and Negative Syndrome Scale. RESULTS: Serum PEA and OEA levels were significantly lower during manic episodes than in healthy controls. During remission, serum PEA and OEA levels did not differ significantly from those of healthy controls. In within-patient comparisons between manic episodes and remission, only serum PEA levels were significantly lower during manic episodes. CONCLUSION: This is the first study to assess serum endocannabinoid levels in patients with BD during both manic episodes and remission, together with healthy controls. PEA and OEA levels were significantly lower during mania and returned to values comparable to healthy controls during remission. These findings suggest that endocannabinoid-related mechanisms may have potential as future biomarkers and therapeutic targets in mood regulation.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.